Board of the College of Pharmacists of British Columbia Regulation

B.C. Reg. 292/2021: Amendments to the Drug Schedules Regulation and Board of the College of Pharmacists of British Columbia. Appendix 1 The Drug Schedules Regulation

Made under the Pharmacy Operations and Drug Scheduling Act

How does this rule affect your organization? One Click reads it against your profile and tells you, on Canada Federal Legislative Tracking. See plans →

Get alerted when the next rule lands

New rules land on their own schedule. Pick how you want to hear about them — we email you when one appears.

Publishing to members? Embed a live rule tracker on your own site — the proposed rules in your area and the comment deadlines closing on them, updating themselves. Free, one line of HTML.

The rule, in full

912 words as published, November 30, 2021. View the original →

B.C. Reg. 292/2021, deposited November 23, 2021, under the PHARMACY OPERATIONS AND DRUG SCHEDULING ACT [section 22]. Resolution of the Board of the College of Pharmacists of British Columbia, dated September 24, 2021. The Board of the College of Pharmacists of British Columbia orders that the Drug Schedules Regulation, B.C. Reg. 9/98, is amended as set out in the attached Appendix. — C. ISHOY, Chair, Board of the College of Pharmacists of British Columbia. Appendix 1 The Drug Schedules Regulation, B.C. Reg. 9/98, is amended in section 2 (3) by striking out the following: Schedule IA (Triplicate/Duplicate Prescription Program): Drugs which may be sold by a pharmacist to a practitioner or on the prescription of a practitioner in accordance with Bylaw 5 (31) (6) of the bylaws to the Pharmacists, Pharmacy Operations and Drug Scheduling Act. and substituting the following: Schedule IA (Triplicate/Duplicate Prescription Program): Drugs which may be sold by a pharmacist to a practitioner or on the prescription of a practitioner in accordance with the bylaws to the Pharmacy Operations and Drug Scheduling Act. 2 The Schedules are amended (a) by striking out the following: 3 Aloe vera latex, its extracts and derivatives (except aloin) (dosage forms for systemic use containing more than 300 mg per dosage unit) 3 Aluminum oxide 3 Belladonna alkaloids, their salts and derivatives for topical use 3 Benzocaine and its salts (for topical use on mucous membranes for teething) 3 Berberis vulgaris (Barberry) 3 Casanthranol 3 Deoxycholic acid and its salts (except when used in an injectable form) 3 Electrolyte solutions (for oral rehydration) 3 Fluoride and its salts (oral preparations containing 1 mg or less of fluoride ion per dosage unit) 2 Fluticasone propionate when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg per metered spray, for individuals 18 years of age and older and in package sizes containing more than 120 metered sprays 3 Fluticasone propionate when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg per metered spray, for individuals 18 years of age and older and in package sizes containing no more than 120 metered sprays 3 Heparin and its salts (for topical use) 3 Hydrocortisone or hydrocortisone acetate (when sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin, for adults and children 2 years of age and over, and in package sizes containing no more than 30 g) 2 Hydroquinone (topical preparations) 3 Iodine and its salts and derivatives (for topical use) 3 Lactic acid (preparations in concentrations of more than 10%) 3 Magnesium citrate (cathartics) 3 Magnesium salicylate (except oral dosage forms which also contain choline salicylate) 3 Narcotine and its salts (Noscapine) 3 Noscapine 3 Povidone - iodine (topical preparations, except in concentrations of 5% or less) 3 Sodium biphosphate (cathartic) 3 Sodium phosphate (cathartics) 1 Vitamin D in oral dosage form containing more than 1 000 International Units of Vitamin D per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by that person of more than 1 000 International Units of Vitamin D , and (b) by adding the following: 3 Acetaminophen and ibuprofen, when sold in oral, fixed-dose combinations, in package sizes containing 20 000 mg or less of acetaminophen and 6 000 mg or less of ibuprofen 2 Acetaminophen and ibuprofen, when sold in oral, fixed-dose combinations, in package sizes containing either more than 20 000 mg of acetaminophen or more than 6 000 mg of ibuprofen 1 Alpha-hydroxy acids, including but not limited to citric acid, glycolic acid, lactic acid, malic acid, mandelic acid, ammonium glycolate, glycolic acid + ammonium glycolate, alpha-hydroxyethanoic acid + ammonium alpha-hydroxyethanoate, alpha-hydroxyoctanoic acid, alpha-hydroxycaprylic acid, hydroxycaprylic acid, mixed fruit acid, triple fruit acid, tri-alpha hydroxy fruit acids, alpha-hydroxy and botanical complex, l-alpha hydroxy acid, glycomer in cross-linked fatty acids alpha nutrium, when sold in topical formulations containing alpha-hydroxy acids alone or in combination at concentrations greater than 30% and/or with a pH lower than 3.0, except when sold to be applied to warts, corns or calluses 2 Fluticasone propionate, when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg per metered spray, for individuals 18 years of age and older and in package sizes containing more than 360 metered sprays 3 Fluticasone propionate, when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg per metered spray, for individuals 18 years of age and older and in package sizes containing no more than 360 metered sprays 1 Hydroquinone or its derivatives, when sold in a concentration greater than 2% in preparations for topical use on the skin 2 Hydroquinone or its derivatives, when sold in a concentration less than or equal to 2% in preparations for topical use on the skin 1 Mometasone furoate for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg per spray for those 12 years of age and older 1 Vitamin D in oral dosage form containing more than 62.5 mcg or 2 500 International Units of Vitamin D per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by that person of more than 62.5 mcg or 2 500 International Units of Vitamin D .